You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Thermo Fisher plans to use the proceeds to pay in part for the acquisition of Qiagen, expected to close in the first half of 2021, and for general corporate purposes.
The funds will go toward general corporate purposes, possibly including repayment of a portion of its outstanding commercial paper borrowings.
The company plans to use the net proceeds to pay in part for its anticipated acquisition of Qiagen, as well as for general corporate purposes.
The company said it will use the proceeds for general corporate purposes, such as the repayment of debt, working capital, and possible acquisitions.
The company intends to use the net proceeds to repay at maturity or redeem its $800 million aggregate principal amount of senior notes due in 2020.
The offering consists of two tranches, $400 million of 2.3 percent senior notes due 2024 and $650 million of 2.95 percent senior notes due 2029.
The firm said that it will use proceeds from the sale to purchase or repay other notes or loans, including up to $300 million in outstanding senior notes.
The company signed a distribution agreement in Japan for its Idylla products and also initiated a listing of €150 million in unsecured convertible bonds.
The company plans to use the financing to fund part of its 21.4 billion pending acquisition of GE Biopharma.
The firm will offer €4.4 billion of euro-denominated notes and $900 million in dollar-denominated notes. It will redeem another $4.5 billion in outstanding notes.